Donald Durden
Professor
Microbiology
Biotech Umea
Sweden
Biography
Dr. Durden is a physician-scientist and Associate Director of Moores UCSD Cancer Center for Pediatric Oncology. He is co-director of MCC and Rady Children‘s Hospital biorepository and center for personalize oncology. His laboratory is focused on the study of PTEN and PI-3 kinase in cancer and human disease. He has been involved in drug discovery, development and clinical and basic cancer research for almost 20 years. He has been continuously funded by the NIH for past 20 years. His laboratory was the first to demonstrate that PTEN controls tumor induced angiogenesis, a pioneering which led him to be first to show antitumor activity of PI-3 kinase inhibitory molecules ultimately resulting in the development of one of the first PI-3 kinase inhibitors, SF1126, to enter human clinical trials. He now in collaboration with SignalRx Pharmaceuticals, Inc. is developing combinatorial inhibitory chemotypes based on observed and/or discovered synthetic lethalities for cancer therapeutics.
Research Interest
Microbiology
